Cepheid is a molecular diagnostics company that develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets. Its solutions enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers a GeneXpert System that integrates sample preparation in addition to DNA amplification and detection. The company also provides a SmartCycler System that integrates DNA amplification and detection to allow the analysis of a sample and Xpert tests for use on the GeneXpert System.

Employee Rating

3.9More
TypeSubsidiary
Parent CompanyDanaher
HQSunnyvale, CA, US
Founded1996
Websitecepheid.com
Cybersecurity ratingAMore
Cepheid was founded in 1996 and is headquartered in Sunnyvale, CA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Cepheid

Annamaria Vaszko

Annamaria Vaszko

Vice President, FP&A

Cepheid Office Locations

Cepheid has offices in Sunnyvale, Geel, São Paulo, Maurens-Scopont and in 10 other locations
Sunnyvale, CA, US (HQ)
Building 1, 904 E Caribbean Dr
Geel, BE
Kleinhoefstraat 5 bus 26
São Paulo, BR
R. Luigi Galvani, 200 - 51 - Itaim Bibi
Maurens-Scopont, FR
Vira Solelh
Frankfurt am Main, DE
Unterlindau 29
New Delhi, IN
DSM 214 - 215, 2 floor, DLF Towers Shivaji Marg, Najafgarh Road
Show all (16)

Cepheid Financials and Metrics

Summary Metrics

Founding Date

1996

Total Funding

$8.1 m

Investors

In total, Cepheid had raised $8.1 m. Cepheid is a subsidiary of Danaher

Cepheid Revenue

Cepheid's revenue was reported to be $538.58 m in FY, 2015 which is a 15% increase from the previous period.
Annual
USDFY, 2015

Revenue

538.6m

Revenue growth, %

15%

Cost of goods sold

269.9m

Gross profit

268.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016

Revenue

144.8m146.0m158.5m

Cost of goods sold

72.6m73.2m83.4m

Gross profit

72.2m72.8m75.1m

Gross profit Margin, %

50%50%47%
Annual
USDFY, 2015

Cash

112.6m

Accounts Receivable

66.6m

Prepaid Expenses

18.5m

Inventories

148.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016

Cash

89.8m100.3m115.7m

Accounts Receivable

72.6m62.8m81.9m

Prepaid Expenses

26.6m23.4m23.1m

Inventories

150.4m156.8m155.7m
Annual
USDFY, 2015

Net Income

(48.5m)

Depreciation and Amortization

33.5m

Inventories

(15.1m)

Accounts Payable

4.2m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016

Net Income

(6.6m)(16.8m)(27.7m)

Depreciation and Amortization

9.0m18.2m28.4m

Inventories

(1.7m)(8.1m)(7.2m)

Accounts Payable

(1.4m)6.0m3.9m
USDFY, 2015

Revenue/Employee

316.8k

Debt/Equity

0.8 x

Debt/Assets

0.4 x

Financial Leverage

2.2 x
Show all financial metrics

Cepheid Operating Metrics

Jun, 2021

Patent Applications (US)

101

Patents (US)

128

Trademarks (US)

2
Show all operating metrics

Cepheid Revenue Breakdown

Embed Graph

Cepheid revenue breakdown by business segment: 15.4% from Clinical Systems, 79.3% from Clinical Reagents and 5.3% from Non-Clinical

Cepheid revenue breakdown by geographic segment: 59.0% from North America and 41.0% from International

Cepheid Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Cepheid Online and Social Media Presence

Embed Graph

Cepheid Company Culture

  • Overall Culture

    C-

    63/100

  • CEO Rating

    F

    42/100

  • Compensation

    D-

    49/100

  • Diversity

    D+

    59/100

Learn more on Comparably

Cepheid News and Updates

Cepheid Announces Updated HBDC Pricing

Today, Cepheid announced that under its High-Burden Developing Country (HBDC) Access Program1,2, the company will make GeneXpert® Systems and customized packages of Xpert® Xpress SARS-CoV-2 and Xpert MTB/RIF Ultra tests available with more accessible pricing.

Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test

SUNNYVALE, Calif., March 21, 2020 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2, the virus...

Cepheid Announces FleXible Cartridge Program

SUNNYVALE, Calif., April 15, 2019 /PRNewswire/ -- Cepheid today announced its FleXible Cartridge program to accelerate menu expansion in Europe and China through partnerships with selected Trusted Reagent Manufacturers (TRMs). Through this program, GeneXpert® System users will gain access ...

Cepheid Receives CE-IVD Clearance for Xpert® HBV Viral Load

SUNNYVALE, Calif., Dec. 20, 2018 /PRNewswire/ -- Cepheid today announced the CE-IVD marking of Xpert HBV Viral Load, a new rapid test for the quantitation of Hepatitis B Virus (HBV) that delivers results in less than an hour. Xpert HBV Viral Load is intended for use as an indicator of...

Cepheid Blogs

Cepheid Receives Health Canada License for SARS-CoV-2, Flu A, Flu B and RSV Combination Test

Challenged by Similar Clinical Presentations, Accurate Detection & Differentiation of all 4 Viruses is Critical for Clinicians This Flu Season

Cepheid Receives Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV Combination Test

Challenged by Similar Clinical Presentations, Accurate Detection & Differentiation of all 4 Viruses is Critical for Clinicians This Flu Season

Cepheid Receives FDA Clearance for Xpert® BCR-ABL Ultra Test

Enabling on-demand monitoring of BCR-ABL levels in patients with Chronic Myeloid Leukemia (CML) SUNNYVALE, CALIF. — Oct. 2, 2019 —  Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden in patients with…

Cepheid Receives CE-IVD clearance for Xpert HCV VL Fingerstick

Enables Hepatitis C Point-of-Care molecular testing and linkage to care. SUNNYVALE, CALIF. — September 19, 2018 —  Cepheid today announced the CE-IVD marking of Xpert HCV VL Fingerstick, the first molecular test to detect and quantify hepatitis C Virus (HCV) RNA levels directly from a fingerstick bl…

International Symposium on Hepatitis Care in Substance Users (INHSU)

September 19th-21st, 2018, Cascais, Portugal
Show more

Cepheid Frequently Asked Questions

  • When was Cepheid founded?

    Cepheid was founded in 1996.

  • Who are Cepheid key executives?

    Cepheid's key executives are Annamaria Vaszko.

  • How many employees does Cepheid have?

    Cepheid has 3,523 employees.

  • What is Cepheid revenue?

    Latest Cepheid annual revenue is $538.6 m.

  • What is Cepheid revenue per employee?

    Latest Cepheid revenue per employee is $152.9 k.

  • Who are Cepheid competitors?

    Competitors of Cepheid include Luminex, OncoCell MDx and HEALTH Gene Technologies.

  • Where is Cepheid headquarters?

    Cepheid headquarters is located at Building 1, 904 E Caribbean Dr, Sunnyvale.

  • Where are Cepheid offices?

    Cepheid has offices in Sunnyvale, Geel, São Paulo, Maurens-Scopont and in 10 other locations.

  • How many offices does Cepheid have?

    Cepheid has 16 offices.